BioGaia Logo

BioGaia

Develops and commercializes clinically proven probiotics for digestive health across all life stages.

BIOG | ST

Overview

Corporate Details

ISIN(s):
SE0017769987 (+1 more)
LEI:
549300UBUJOY2L7TT361
Country:
Sweden
Address:
Box 3242, 103 64 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BioGaia is a biotechnology company specializing in the research, development, and commercialization of probiotic products. Since its founding in 1990, the company has focused on developing clinically proven probiotics to support digestive health and overall well-being for all life stages. Its product portfolio is based on patented strains of Lactobacillus, with key offerings like the BioGaia Protectis® line. This includes probiotic drops for infants, which are researched to help with common digestive issues such as colic, constipation, and diarrhea. BioGaia positions itself as a science-driven leader in its field, providing products that help maintain a healthy intestinal microflora.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-10-22 08:00
Quarterly Report
Swedish 1.6 MB
2025-10-22 08:00
Quarterly Report
English 1.5 MB
2025-08-22 17:30
Post-Annual General Meeting Information
Extra bolagsstämma i BioGaia
Swedish 149.3 KB
2025-08-22 17:30
Board/Management Information
Extraordinary General Meeting of BioGaia
English 71.0 KB
2025-07-25 09:31
Pre-Annual General Meeting Information
Kallelse till extra bolagsstämma i BioGaia AB (publ)
Swedish 169.8 KB
2025-07-25 09:31
Pre-Annual General Meeting Information
Notice to attend the Extraordinary General Meeting of BioGaia AB (publ)
English 199.0 KB
2025-07-18 08:01
Interim Report
Swedish 20.6 MB
2025-07-18 08:01
Interim Report
English 18.4 MB
2025-06-18 14:20
Major Shareholding Notification
Swedish 10.0 KB
2025-05-30 11:00
Declaration of Voting Results & Voting Rights Announcements
Förändrat antal röster i BioGaia AB (publ)
Swedish 261.2 KB
2025-05-30 11:00
Declaration of Voting Results & Voting Rights Announcements
Change in the number of votes in BioGaia AB (publ)
English 231.4 KB
2025-05-21 14:04
Declaration of Voting Results & Voting Rights Announcements
Swedish 10.0 KB
2025-05-20 13:01
Major Shareholding Notification
Swedish 10.7 KB
2025-05-14 16:43
Declaration of Voting Results & Voting Rights Announcements
Swedish 10.0 KB
2025-05-12 16:39
Major Shareholding Notification
Swedish 10.0 KB

Automate Your Workflow. Get a real-time feed of all BioGaia filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioGaia

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioGaia via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-05-08 Barbro Fridén Other Buy 188 19,627.20 SEK
2024-09-13 Linda Hägglund Other Sell 2,000 233,800.00 SEK
2024-09-12 Linda Hägglund Other Sell 994 115,502.80 SEK
2024-09-12 Linda Hägglund Other Sell 6 697.80 SEK
2024-06-10 Outi Armstrong Other Buy 1,000 125,400.00 SEK
2023-08-02 Anthon Jahreskog Other Buy 481 51,515.10 SEK
2023-08-02 Anthon Jahreskog Other Buy 169 18,083.00 SEK

Peer Companies

Company Country Ticker View
AprilBio Co.,Ltd. Logo
Develops long-acting biologic drugs for autoimmune diseases and oncology using its SAFA™ platform.
South Korea 397030
Aprogen Biologics Inc. Logo
Develops and manufactures novel biologic drugs and biosimilars for the professional market.
South Korea 003060
Aprogen, Inc Logo
Develops and manufactures novel biologics and biosimilars for cancer and arthritis treatments.
South Korea 007460
Develops drugs for fibrosis, inflammation, and cancer using NOX inhibitor & CAF modulation tech.
South Korea 293780
Aptahem AB Logo
Develops RNA aptamers to treat acute, life-threatening conditions like sepsis.
Sweden APTA
Aptamer Sciences Inc Logo
Develops aptamer-based therapeutics and diagnostics for oncology and solid tumors.
South Korea 291650
Aptevo Therapeutics Inc. Logo
Developing multi-specific antibody immunotherapies for hematologic and solid tumor cancers.
United States of America APVO
Aptorum Group Ltd Logo
Biopharma developing novel therapeutics for oncology, infectious and metabolic diseases.
United States of America APM
Aquestive Therapeutics, Inc. Logo
Develops oral film drugs for CNS disorders and severe allergies.
United States of America AQST
Arbutus Biopharma Corp Logo
A clinical-stage virology company developing a functional cure for chronic hepatitis B (HBV).
United States of America ABUS

Talk to a Data Expert

Have a question? We'll get back to you promptly.